SAT-811 Characterizing Patients With Thyroid Eye Disease Initiating Treatment With Teprotumumab: A Retrospective Cohort Study Using Linked Academy IRIS® Registry And Komodo Claims Data

Abstract Disclosure: L. Mawn: Amgen Inc, Genentech, Inc. E.M. Shriver: Amgen Inc, Genentech, Inc. M. Tamhankar: Amgen Inc, Genentech, Inc., Viridian Therapeutics, argenx. Y. Yuan: Amgen Inc. A. Xi: Amgen Inc. J. Ayala-Haedo: Amgen Inc. H. Patel: Amgen Inc. Introduction: Thyroid eye disease (TED) is a progressive and debilitating autoimmune disease. Teprotumumab (TEP), an insulin-like growth factor-1 receptor inhibitor, was approved by the US Food and Drug Administration in January 2020 as the first targeted TED therapy. Aim: Examine baseline characteristics among patients (pts) prior to TEP initiation. Methods: A retrospective cohort study was performed using linked data from American Academy of Ophthalmology IRIS ® Registry (Intelligent Research in Sight) and Komodo Health claims. Adult pts initiating TEP between 1/1/2020 and 12/31/2023 were identified in Komodo with the first TEP infusion as the index date. Continuous enrollment in Komodo ≥12 mos before (baseline) and after (follow-up) the index date was required. Pt demographics, eye signs/symptoms (sx), and treatment history were described at index or baseline. Clinical activity score (CAS) and proptosis measurements were identified from the IRIS Registry within 60 days before or on index date, with CAS ≥3 on 7-scale or ≥4 on 10 defined as active. TED diagnosis at index was categorized as shorter (diagnosis < 24 mos before index) or longer duration (≥ 24 mos). All study variables were analyzed descriptively for overall cohort and stratified by TED duration at index. Results: 2,886 pts initiated TEP: 77% were female, 56% white, median age 60 years, 75% with shorter duration TED. Most pts had commercial insurance (48%) or Medicare (38%). Top baseline comorbidities were hyperthyroidism (98%), hypertension (45%), history of smoking/nicotine or tobacco use (25%), type 2 diabetes (17%), and hearing impairment/loss (8%). 80% of pts had ≥1 baseline eye signs/sx, with proptosis (45%), diplopia (29%) and lid retraction (29%) being the most common. Among pts with CAS (N=356) and proptosis measurement (N=511) available, 91% were active and 66% had measurement(s) >21mm. History of receiving high-dose steroids or TED surgeries was 9% and <5%, respectively. Similar demographics and comorbidities were observed among pts with shorter vs. longer duration. More longer duration pts had ≥3 signs/sx at baseline (48% vs. 36%) or previously had TED surgeries (14% vs. 4%) when compared to shorter duration pts. Conclusions: Pts initiating TEP had high baseline clinical burden, with the majority having one or more eye signs/sx and active disease regardless of TED duration. Further analyses are needed to characterize TEP treatment patterns and the impact of TEP on clinical outcomes in the real world. Presentation: Saturday, July 12, 2025